670 KB, PDF document
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Targeting the Cell Cycle in the Pursuit of Novel Chemotherapies against Parasitic Protozoa.
AU - Grant, Karen M.
PY - 2008
Y1 - 2008
N2 - Protozoan parasites, such as those responsible for malaria and African Sleeping Sickness, represent a huge burden to the developing world. Current chemotherapy to combat these diseases is inadequate: antiquated, toxic and increasingly ineffective due to drug resistance. In this article, the potential usefulness of targeting key regulators of the parasite cell cycle will be discussed, paying particular attention to three families of protein kinases: Cyclin-dependent kinases, glycogen synthase kinases and Aurora kinases. This review shall outline their identification, which has been greatly accelerated by the availability of parasite genome data, their validation as bona fide regulators of the parasite cell cycle and current data on the availability and anti-parasite activity of inhibitors.
AB - Protozoan parasites, such as those responsible for malaria and African Sleeping Sickness, represent a huge burden to the developing world. Current chemotherapy to combat these diseases is inadequate: antiquated, toxic and increasingly ineffective due to drug resistance. In this article, the potential usefulness of targeting key regulators of the parasite cell cycle will be discussed, paying particular attention to three families of protein kinases: Cyclin-dependent kinases, glycogen synthase kinases and Aurora kinases. This review shall outline their identification, which has been greatly accelerated by the availability of parasite genome data, their validation as bona fide regulators of the parasite cell cycle and current data on the availability and anti-parasite activity of inhibitors.
KW - Cyclin-dependent kinase Glycogen synthase kinase Aurora kinase cell cycle Trypanosoma Leishmania Plasmodium
M3 - Journal article
VL - 14
SP - 917
EP - 924
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
SN - 1873-4286
IS - 9
ER -